CordenPharma _________________________________________________________________________________________________
Insertion Peptide ( pHLIP ®) targeted delivery technology to formulate pHLIP-coated LNPs for use by biopharmaceutical companies seeking to deliver mRNA-based and gene therapy payloads .
New facility
“ Such payloads can be used to treat cancer , inflammation , and genetic diseases , or to employ mRNA strategies for vaccination ,” he continues . “ We believe this novel pHLIP-LNP platform will greatly enhance the commercial viability and success of many pioneering RNA , DNA , and CRISPR therapies . It will also enable us to collaborate in developing and manufacturing small molecule drug payloads directly conjugated with peptides for biopharmaceutical companies seeking to selectively target cells in acidic diseased tissues . We already serve as the CDMO supplier in the GMP manufacture of peptides , drug conjugates , LNPs , and fill and finish , so this new alliance further builds upon our collaborative efforts .”
Aside from the alliance with pHLIP , CordenPharma is exploring investment in several areas . “ Our integrated network of facilities brings more than 200 years of experience to our projects , as well as 1.2 million liters of volumetric capacity and reactors ranging from 20 liters to 28,000 liters ,” Matthieu explains . “ Acknowledging the importance of LNPs as a key delivery platform for the therapeutics of the future , we initiated a strategic investment program at our sterile injectable site in Caponago , Italy , in 2020 , to establish LNP formulation , development , and manufacturing facilities .
“ Similarly , to further support the clinical and potentially commercial demand of LNPbased therapeutics , we began building a new GMP LNP manufacturing suite in 2022 by extending an existing GMP area . The new site is strategically placed adjacent to the clinicalscale fill and finish facility to streamline endto-end manufacturing operations from cargo molecule encapsulation to fill and finish in the final primary packaging container .”
Ambitious growth
As Matthieu looks to the future of CordenPharma , he reflects on the last 12 months . “ 2023 was a transformational year for us , which in many ways laid the foundation for our accelerated growth trajectory ,” he says . “ Most notably , we contributed to the launch of several new medicines for small to large patient populations , ranging from innovative orphan drugs with high unmet medical needs to breakthrough diabetes and obesity products . Throughout these projects , our purpose as a leading CDMO brought important value to innovators across the pharmaceutical supply chain .
“ This year , we are continuing to pursue our ambitious growth , and as part of a longterm strategic objective , we are striving for exceptional customer experience and strengthening our commitment to ESG , with a plan to imminently announce our SBTi targets ,” Matthieu concludes . “ Furthermore , we will continue to attract top talent and enhance our company culture through our people strategy . After all , it is the passion of people across CordenPharma and the wider industry that truly makes the difference in the lives of patients .” ■
cordenpharma . com
92